Adaptive biotechnologies stock.
Nov 29, 2023 · In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock. Percentage Held by Insiders. Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders. Percentage Held by Institutions
The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is an Overweight stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight.Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of t...Oct 17, 2023 · The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter. Jun 30, 2023 · Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year.
Hardly a day in March has gone by without Wood making purchases of Adaptive Biotechnologies (ADPT 7.31%), Burning Rock Biotech (BNR-0.12%), or both. ... Get stock recommendations, portfolio ...
Adaptive Biotechnologies (ADPT Quick Quote ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a ...
Taking the right travel adapter with you will ensure you're never without — but with so many types, it can be tricky to know what you need. We may be compensated when you click on product links, such as credit cards, from one or more of our...Adaptive Biotechnologies ( ADPT) reported Q3 2023 earnings per share (EPS) of -$0.35, missing estimates of -$0.34 by 2.64%. In the same quarter last year, Adaptive Biotechnologies 's earnings per share (EPS) was -$0.32. Adaptive Biotechnologies is expected to release next earnings on 02/19/2024, with an earnings per share (EPS) …52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS Feeds.Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation...Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings …
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...
Apr 15, 2022 · Adaptive Biotechnologies sports a market-leading advantage with its one-of-a-kind proprietary tech. The company's stock has been smashed in the last year losing over two-thirds of its share price.
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. Date.Mar 31, 2023 · As of March 31, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.83. Adaptive Biotechnologies Corp is up 4.87% from its previous closing price of $8.42. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.21 and $8.67. Currently, there are 143.06 million shares of Adaptive ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Adaptive Biotechnologies Corporation . 2019 Employee Stock Purchase Plan . 1. ESTABLISHMENT, PURPOSE AND TERM OF PLAN.. 1.1 Establishment. The Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan is hereby established effective as of the effective date of the initial registration by the Company of its Stock …Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year.Mar 9, 2023 · Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ...
Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.... shares and is commonly used to measure how much a company is worth. Market cap history of Adaptive Biotechnologies from 2019 to 2023. 2020 2021 2022 2023 $2B ...Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago.The institutional investor acquired 53,400 shares of the company’s stock, corresponding to a value of approximately $472,000. Adaptive Biotechnologies Co., listed on NASDAQ under the symbol ADPT, opened at $6.17 on Tuesday. Over the past year, its stock has ranged between a low of $5.96 and a high of $10.79.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic …
Adaptive Biotechnologies (ADPT) is a biotech company that develops an immune medicine platform for various diseases. The stock has a consensus rating of …
The estimated net worth of Chad M. Cohen is at least $134,139.07 as of September 7th, 2021. Mr. Cohen owns 30,979 shares of Adaptive Biotechnologies stock worth more than $134,139 as of November 28th. This net worth evaluation does not reflect any other investments that Mr. Cohen may own. Learn More about Chad M. Cohen's net …DOI: 10.1200/JCO.21.00377 Journal of Clinical Oncology - published online before print June 16, 2021 . PMID: 34133196Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine. Adaptive Biotechnologies ( NASDAQ: ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. The Seattle-based life ...So consider, for a moment, the misfortune of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) investors who have held the stock for three years as it declined a whopping 82%.Mr. Goel ADPT stock SEC Form 4 insiders trading. David has made over 6 trades of the Adaptive Biotechnologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 466,176 units of ADPT stock worth $13,463,163 on 14 May 2014.. The largest trade he's ever made was selling 1,000,000 units of Adaptive …Adaptive Biotechnologies is expected to report sales of $18.8 million, an decrease of 15.09% over the same period last year. With regard to the current fiscal year, analysts forecast a loss per ...SEATTLE, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering …Find the latest Institutional Holdings data for Adaptive Biotechnologies Corporation Common Stock (ADPT) at Nasdaq.com.Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...
Adaptive Biotechnologies Corporation (ADPT) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » ADPT Adaptive …
Adaptive’s layoffs come as a hot biotech IPO market during 2021 cools down and biotech stock values decline. One key biotech index fund, the SPDR S&P Biotech ETF (XBI), is down about 50% from ...
Adaptive Biotechnologies announced its first quarter earnings Wednesday, ... Adaptive’s stock value at market close Wednesday was $9.25, down from its high in February 2021 of nearly $70.Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen closed nearly 83% …Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. …Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic ...Transcript : Adaptive Biotechnologies Corporation, Q4 2022 Earnings Call, Feb 14, 2023 February 14, 2023 at 04:30 pmJun 2, 2023 · SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ... Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine. Adaptive Biotechnologies Chief Scientific Officer Harlan Robins signs the final beam during a “topping off” ceremony at the company’s future headquarters on Thursday, 23, 2020 in Seattle ...Taking the right travel adapter with you will ensure you're never without — but with so many types, it can be tricky to know what you need. We may be compensated when you click on product links, such as credit cards, from one or more of our...Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...
Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing.Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …Adaptive Biotechnologies (NASDAQ: ADPT) $4.31 (6.9%) $0.28 Price as of November 17, 2023, 4:00 p.m. ET Overview Return vs. S&P News & Analysis Financial Health …Ms. Taylor ADPT stock SEC Form 4 insiders trading. Stacy has made over 25 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 18,878 units of ADPT stock worth $162,162 on 6 March 2023.. The largest trade she's ever made was exercising 19,580 units of Adaptive …Instagram:https://instagram. kre stocksone dollar coin 1921 valueallo.stockquarters of value SEATTLE, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public …Adaptive Biotechnologies Next up, Wood has been leaning into a leader in a rapidly emerging field. Adaptive Biotechnologies is a pioneering commercial-stage biotech company at the forefront of ... can i get a heloc after refinancingotcmkts tcnnf compare Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2022 and December 31, 2021; 142,784,868 and 141,393,865 shares issued and outstanding at June 30, 2022 and … arcutis biotherapeutics stock Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ...Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20.